Overview

Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer

Status:
Unknown status

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

We presumed that the addition of a monoclonal antibody Bevacizumab into radiation therapy and combination chemotherapy could results in improved pathologic tumor regression grade (TRG) in locally advanced nonmetastatic rectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin